0000950159-23-000317.txt : 20231211 0000950159-23-000317.hdr.sgml : 20231211 20231211060055 ACCESSION NUMBER: 0000950159-23-000317 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231210 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231211 DATE AS OF CHANGE: 20231211 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cigna Group CENTRAL INDEX KEY: 0001739940 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 824991898 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38769 FILM NUMBER: 231476822 BUSINESS ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 BUSINESS PHONE: 8602266000 MAIL ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 FORMER COMPANY: FORMER CONFORMED NAME: Cigna Corp DATE OF NAME CHANGE: 20181221 FORMER COMPANY: FORMER CONFORMED NAME: Halfmoon Parent, Inc. DATE OF NAME CHANGE: 20180508 8-K 1 cigna8k.htm THE CIGNA GROUP FORM 8-K
false 0001739940 0001739940 2023-12-10 2023-12-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

 

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) December 10, 2023

 

The Cigna Group

 

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of

incorporation)

001-38769

(Commission File Number)

82-4991898

(IRS Employer

Identification No.)

 

900 Cottage Grove Road

Bloomfield, Connecticut 06002

 

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code:

 

(860) 226-6000

 

Not Applicable

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, Par Value $0.01 CI New York Stock Exchange, Inc.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 

 

Item 7.01 Regulation FD Disclosure.

 

2023 Outlook Affirmation 

On December 10, 2023, The Cigna Group (the “Company” or “our”) reaffirmed projected full year 2023 consolidated adjusted income from operations on a per share basis of at least $24.75 per share and targeted consolidated adjusted income from operations on a per share basis of at least $28.00 for full-year 2024.

The Cigna Group previously discussed its full year 2023 outlook in its press release and investor presentation dated November 2, 2023, and during the related investor conference call. The press release, presentation and the conference call transcript are available in the Investor Relations section of The Cigna Group’s website located at www.thecignagroup.com. Forward-looking statements in these documents and the related call speak only as of the date they were made.

Adjusted income (loss) from operations is a principal financial measure of profitability used by The Cigna Group’s management because it presents the underlying results of operations of the Company’s businesses and permits analysis of trends in underlying revenue, expenses and shareholders’ net income. Adjusted income from operations is defined as shareholders’ net income (or income before taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net realized investment results, amortization of acquired intangible assets and special items. The Cigna Group’s share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders’ net income.

Management is not able to provide a reconciliation of adjusted income from operations to shareholders’ net income (including on a per share basis) on a forward-looking basis because we are unable to predict, without unreasonable effort, certain components thereof including (i) future net realized investment results (from equity method investments with respect to adjusted revenues) and (ii) future special items. These items are inherently uncertain and depend on various factors, many of which are beyond our control. As such, any associated estimate and its impact on shareholders’ net income could vary materially.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date of this report, except as shall be expressly set forth by specific reference in such a filing.

Share Repurchase

On December 10, 2023, the Company issued a press release announcing that the Board of Directors approved an aggregate increase of $10 billion in incremental share repurchase authorization, bringing the Company's total share repurchase authority to $11.3 billion. The Company intends to use the majority of its discretionary cash flow for share repurchase in 2024. The Company expects this to include repurchase of at least $5 billion of common stock between now and the end of the first half of 2024, with a portion of this repurchase to be executed via an accelerated share repurchase program conducted in the first quarter of 2024.   

The Company’s proposed repurchases under the updated share repurchase program may be made from time to time on the open market at prevailing market prices, through accelerated share repurchase agreements, in privately negotiated transactions, in block trades, and/or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations and its insider trading policy. The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and alternate uses of capital. The program may be suspended or discontinued at any time.

   

 

The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date of this Current Report on Form 8-K, except as shall be expressly set forth by specific reference in such a filing.

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS


This Current Report on Form 8-K (the “Report”), and oral statements made with respect to information contained in this Report, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning our projected adjusted income from operations outlook for 2023 on a consolidated, per share, and segment basis; targeted adjusted income from operations outlook for 2024 on a per share basis; projected weighted average shares outstanding; future share repurchase and future dividends; future financial or operating performance, including our ability to improve the health and vitality of those we serve; future growth, business strategy and strategic or operational initiatives; economic, regulatory or competitive environments, particularly with respect to the pace and extent of change in these areas and the impact of developing inflationary and interest rate pressures; financing or capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; strategic transactions; expectations related to our Medicare Advantage Capitation Rates; and other statements regarding The Cigna Group’s future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as “believe,” “expect,” “project,” “plan,” “intend,” “anticipate,” “estimate,” “predict,” “potential,” “may,” “should,” “will” or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our strategic and operational initiatives; our ability to execute the contemplated share repurchases, including the contemplated accelerated share repurchase program, on attractive terms, on the anticipated timing or at all; our ability to adapt to changes in an evolving and rapidly changing industry; our ability to compete effectively, differentiate our products and services from those of our competitors and maintain or increase market share; price competition, inflation and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with physicians, hospitals, other health service providers and with producers and consultants; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; changes in drug pricing or industry pricing benchmarks; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; potential liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; uncertainties surrounding participation in government-sponsored programs such as Medicare; the outcome of litigation, regulatory audits and investigations; compliance with applicable privacy, security and data laws, regulations and standards; potential failure of our prevention, detection and control systems; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on employment metrics, stock market or changes in interest rates and risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent report on Forms 10-Q and 8-K available through the Investor Relations section of www.thecignagroup.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.

   

 

 

 

Item 9.01 Financial Statements and Exhibits.


(d) Exhibits

 

  
Exhibit No. Description
99.1

Press release issued December 10, 2023

 

104 Cover Page Interactive Data File (embedded within the Inline XBRL)
     

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  THE CIGNA GROUP
     
Date:  December 11, 2023 By: /s/ Brian C. Evanko
    Brian C. Evanko
    Executive Vice President and Chief Financial Officer

 

 EX-99.1 2 ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

The Cigna Group Announces Significant Increase to Share Repurchase Program of $10 Billion

The Cigna Group (PRNewsfoto|The Cigna Group)

Intends to Repurchase at Least $5 Billion of Common Stock by End of First Half of 2024, 
with Portion Executed Via ASR in First Quarter 2024

Reaffirms Previously Provided Outlook for Full-Year 2023

BLOOMFIELD, Conn., Dec. 10, 2023 /PRNewswire/ -- Global health company The Cigna Group (NYSE: CI) today announced that its Board of Directors has approved an aggregate increase of $10 billion in incremental share repurchase authorization, bringing the company's total share repurchase authority to $11.3 billion. The company intends to use the majority of its discretionary cash flow for share repurchase in 2024. The company expects this to include repurchase of at least $5 billion of common stock between now and the end of the first half of 2024, with a portion of this repurchase to be executed via an accelerated share repurchase program conducted in the first quarter of 2024.  

"We believe Cigna's shares are significantly undervalued and repurchases represent a value-enhancing deployment of capital as we work to support high-quality care, improved affordability, and better health outcomes," said David M. Cordani, Chairman and Chief Executive Officer, The Cigna Group. "As we look at the broader landscape and the strategic opportunities before us, we will remain financially disciplined with a clear focus on executing against our strategy, delivering value for our shareholders, and investing in our future. In light of the current environment, we will consider bolt-on acquisitions aligned with our strategy, as well as value-enhancing divestitures." 

   

 

 

In connection with today's announcement, Cigna reaffirmed its previously provided outlook of full-year 2023 consolidated adjusted income from operations on a per share basis of at least $24.75 per share. The company continues to target consolidated adjusted income from operations on a per share basis of at least $28 for full-year 2024.

Added Cordani, "Over the past 10 years, our consistent execution has resulted in EPS growth of more than 13 percent on an annualized basis, demonstrating our ability to profitably evolve our business and the services we provide. We are confident in the ongoing growth and strength of Cigna's businesses and expect to carry significant momentum forward into 2024. This conviction reinforces the confidence we have in achieving our long-term annual adjusted EPS growth target of 10-13% while maintaining an attractive dividend."

The company's proposed repurchases under the updated share repurchase program may be made from time to time on the open market at prevailing market prices, through accelerated share repurchase agreements, in privately negotiated transactions, in block trades, and/or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations and its insider trading policy.

Forward-Looking Statements

This press release, and oral statements made in connection with this release, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning our projected adjusted income from operations outlook for 2023 on a consolidated, per share, and segment basis; targeted adjusted income from operations outlook for 2024 on a per share basis; projected weighted average shares outstanding; future share repurchase and future dividends; future financial or operating performance, including our ability to improve the health and vitality of those we serve; future growth, business strategy and strategic or operational initiatives; economic, regulatory or competitive environments, particularly with respect to the pace and extent of change in these areas and the impact of developing inflationary and interest rate pressures; financing or capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; strategic transactions; expectations related to our Medicare Advantage Capitation Rates; and other statements regarding The Cigna Group's future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as "believe," "expect," "project," "plan," "intend," "anticipate," "estimate," "predict," "potential," "may," "should," "will" or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our strategic and operational initiatives; our ability to execute the contemplated share repurchases, including the contemplated accelerated share repurchase program, on attractive terms, on the anticipated timing or at all; our ability to adapt to changes in an evolving and rapidly changing industry; our ability to compete effectively, differentiate our products and services from those of our competitors and maintain or increase market share; price competition, inflation and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered

   

 

 

to our customers; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with physicians, hospitals, other health service providers and with producers and consultants; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; changes in drug pricing or industry pricing benchmarks; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; potential liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; uncertainties surrounding participation in government-sponsored programs such as Medicare; the outcome of litigation, regulatory audits and investigations; compliance with applicable privacy, security and data laws, regulations and standards; potential failure of our prevention, detection and control systems; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on employment metrics, stock market or changes in interest rates and risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available through the Investor Relations section of www.thecignagroup.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.

Notes:

  1. Adjusted income (loss) from operations is a principal financial measure of profitability used by The Cigna Group's management because it presents the underlying results of operations of the Company's businesses and permits analysis of trends in underlying revenue, expenses and shareholders' net income. Adjusted income from operations is defined as shareholders' net income (or income before taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net realized investment results, amortization of acquired intangible assets and special items. The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders' net income.
   

 

  1. Management is not able to provide a reconciliation of adjusted income from operations to shareholders' net income (including on a per share basis (EPS)) or adjusted revenues to total revenues on a forward-looking basis because we are unable to predict, without unreasonable effort, certain components thereof including (i) future net realized investment results (from equity method investments with respect to adjusted revenues) and (ii) future special items. These items are inherently uncertain and depend on various factors, many of which are beyond our control. As such, any associated estimate and its impact on shareholders' net income and total revenue could vary materially.

INVESTOR RELATIONS CONTACT:
Ralph Giacobbe
860-787-7968
Ralph.Giacobbe@TheCignaGroup.com

MEDIA CONTACT:
Justine Sessions
860-810-6523
Justine.Sessions@Evernorth.com

 

 GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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ci-20231210.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 ci-20231210_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 ci-20231210_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Dec. 10, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 10, 2023
Entity File Number 001-38769
Entity Registrant Name The Cigna Group
Entity Central Index Key 0001739940
Entity Tax Identification Number 82-4991898
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 900 Cottage Grove Road
Entity Address, City or Town Bloomfield
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06002
City Area Code 860
Local Phone Number 226-6000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.01
Trading Symbol CI
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 8 cigna8k_htm.xml IDEA: XBRL DOCUMENT 0001739940 2023-12-10 2023-12-10 iso4217:USD shares iso4217:USD shares false 0001739940 8-K 2023-12-10 The Cigna Group DE 001-38769 82-4991898 900 Cottage Grove Road Bloomfield CT 06002 860 226-6000 false false false false Common Stock, Par Value $0.01 CI NYSE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / " M 4(0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " ;,(M7)!Z;HJT #X M 0 &@ @ &B$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'-02P$"% ,4 " ;,(M799!YDAD! #/ P $P @ &' L$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #1$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://thecignagroup.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ci-20231210.xsd ci-20231210_lab.xml ci-20231210_pre.xml cigna8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "cigna8k.htm": { "nsprefix": "CI", "nsuri": "http://thecignagroup.com/20231210", "dts": { "schema": { "local": [ "ci-20231210.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "ci-20231210_lab.xml" ] }, "presentationLink": { "local": [ "ci-20231210_pre.xml" ] }, "inline": { "local": [ "cigna8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://thecignagroup.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-12-10", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "cigna8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-10", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "cigna8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0000950159-23-000317-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950159-23-000317-xbrl.zip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end